Skip to main content

Table 1 Clinicopathological characteristics of patients, primary breast tumours, and treatment

From: p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer

   Number of patients (percentage)
Total number of patients   73
Age at diagnosis (years) ≤50
>50
34 (46.6)
39 (53.4)
  Range 29 to 77
Tumour size (cm) <2.0
≥2.0
20 (27.4)
53 (72.6)
Number of positive lymph nodes 0
1–3
>3
21 (28.8)
20 (27.4)
32 (43.8)
Histological grade 1
2
3
12 (16.4)
42 (57.5)
19 (26.1)
Adjuvant therapy None
Endocrine therapy
Chemotherapy
Combined
5 (6.9)
32 (43.8)
2 (2.7)
34 (46.6)
Disease-free interval (months) Mean ± SD
Median
39.8 ± 25.7
38
  Range 2 to 123
First-line endocrine therapy for metastatic breast cancer Tamoxifen
Aromatase inhibitors
LHRH agonist
LHRH agonist + tamoxifen
Fulvestrant
56 (76.7)
9 (12.3)
3 (4.1)
4 (5.5)
1 (1.4)
  1. LHRH, luteinising hormone-releasing hormone; SD, standard deviation.